Quotient Sciences
Faster Transition from Molecules to Cure

Denise Sutton, COO

Quotient Sciences operates with an unswerving belief that molecules need to become cures faster. For that, the company combines science, agility, and innovation to provide a comprehensive array of services such as drug substance synthesis, formulation development, clinical pharmacology, and clinical and commercial manufacturing services – which can be fully integrated with Quotient’s Translational Pharmaceutics™—platform, to reduce net cost and improve operational efficiency in drug development.

Quotient integrates its services through three stages of the drug development process. Firstly, in Candidate Selection, Quotient enables clients to select the most suitable molecules to progress into development by conducting a holistic scientific assessment of the lead molecules and identifying any red flags. This mitigates the risks of failure for the client and shortens the lead times of development. Secondly, in Early Development, Quotient accelerates the transition of molecules through first-in-human trials and into Proof-of-Concept (POC) trials with integrated drug substance, drug product and clinical testing activities. The tight integration of CMC and clinical workflows means that real-time human data drives product development decisions.

We don’t hide from problems. We run towards the fire. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast

Delivering exceptional science and operational agility are core principles of Quotient Sciences, which are deeply embedded in the company’s culture. This was demonstrated when a client approached Quotient regarding a pediatric clinical trial for the treatment of liver diseases. The children were critically ill, and they urgently needed personalised medication based on their individual weight. Quotient configured a real-time manufacturing program for the drug in which individual patient packs were manufactured with less than 14 days notice, and the drug product was delivered to nine countries, across twenty-seven clinical trial sites, involving more than a thousand discreet patients. Explaining the project further, Denise Sutton, COO of Quotient Sciences, adds, “It was something that the team found really emotional. We became an extended part of the customer’s project team, delivering medicine for these children across the globe.” After the clinical trial was complete, Quotient Sciences went on to provide what can be called “compassionate supply”, giving the patients continued access to the treatment. This type of project embodies the Quotient mindset - thinking outside the box, finding ways to simplify the drug development processes for its clients and getting medicines to patients faster.

Quotient Sciences recently acquired Arcinova—an agile Contract Development & Manufacturing Organisation (CDMO)—that provides the pharmaceutical industry with integrated and specialist services throughout the drug development pipeline. Together as one company, they aim to continue breaking down traditional drug development silos and further optimise the development and manufacturing processes. Quotient Sciences fosters relationships with its customers and will continue to listen to its customers, understand their challenges and then make investment decisions to help address their needs. This could include adding new capabilities, equipment or operating in new geographies. Denise concludes, “We don’t hide from problems, we run towards the fire. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.”